<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02294370</url>
  </required_header>
  <id_info>
    <org_study_id>Botnia012014</org_study_id>
    <nct_id>NCT02294370</nct_id>
  </id_info>
  <brief_title>Variation of Glucose Values at Early Stages of Diabetes - Continuous Glucose Monitoring</brief_title>
  <official_title>Glucose Excursions at Early Stages of Diabetes, MOSAIC Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Folkhälsan Researech Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Politecnica de Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Salvatore Maugeri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asociación Española Para el Desarrollo de la Epidemiologia Clínica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soluciones Tecnologias para la Salud y el Bienestar SA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Technical University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Folkhälsan Researech Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at improving the prediction of type 2 diabetes among high-risk individuals by
      examining glucose excursion patterns in subjects with impaired glucose tolerance. In
      addition, this study will show whether the currently used diagnostic test could be replaced
      by an easier and less expensive method.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes is a chronic disease of glucose metabolism leading to various disabling
      conditions. The onset of type 2 diabetes is a gradual shift from normal to abnormal, giving
      rarely noticeable symptoms at its early stages or even in later stages when damage has
      already been caused. Due to the gradual onset, the diagnosis is often delayed, and as much as
      half of the asymptomatic patients remain undetected. The diagnostic criteria for diabetes are
      based on artificial boundaries reflecting the risk of complications related to diabetes. The
      golden standard of diagnosis of diabetes is a 2 hours oral glucose tolerance test, which is
      both time consuming and costly. This study aims at improving the prediction of type 2
      diabetes among high-risk individuals by examining glucose excursion patterns in subjects with
      impaired glucose tolerance. In addition, this study will show whether the currently used
      diagnostic test could be replaced by an easier and less expensive method.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>glucose levels in tissue fluid</measure>
    <time_frame>continuous monitoring for 1 week</time_frame>
    <description>continuous glucose monitoring system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>capillary glucose</measure>
    <time_frame>4 times a day for 1 week</time_frame>
    <description>for the calibration of the continuous glucose monitoring system</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">62</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>subjects at the early stages of diabetes</arm_group_label>
    <description>Subjects at the early stages of diabetes, individuals with impaired glucose tolerance (IGT, 2h plasma glucose during oral glucose tolerance test &gt;7.8-11.1 mmol/l (n=50) or with type 2 diabetes (fasting plasma glucose &gt; 7.0 mmol/l and/or 2h plasma glucose &gt; 11.1 mmol/l on two occasions, or both criteria fulfilled in same oral glucose tolerance test while not pregnant, n=50) with short duration (&lt;3 years)</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with impaired glucose tolerance (2h plasma glucose during oral glucose
        tolerance test &gt;7.8-11.1 mmol/l, n=50) or with type 2 diabetes (fasting plasma glucose &gt;
        7.0 mmol/l and/or 2h plasma glucose &gt; 11.1 mmol/l on two occasions, or both criteria
        fulfilled in the same oral glucose tolerance test while not pregnant, n=50) with short
        duration (&lt;3 years); 40 from Padova University Hospital, 60 from the Botnia Study or the
        PPP-Botnia Study in Finland. The Botnia Study and the PPP-Botnia Study are population based
        studies investigating type 2 diabetes in western Finland.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with impaired glucose tolerance (2h plasma glucose during oral glucose
             tolerance test &gt;7.8-11.1 mmol/l, n=50) or with type 2 diabetes (fasting plasma glucose
             &gt; 7.0 mmol/l and/or 2h plasma glucose &gt; 11.1 mmol/l on two occasions, or both criteria
             fulfilled in the same oral glucose tolerance test while not pregnant, n=50) with short
             duration (&lt;3 years); 40 from Padova University Hospital, 60 from the Botnia Study or
             the PPP (Prevalence, Prediction, Prevention)-Botnia Study in Finland.

          -  Age 40-75 years

        Exclusion Criteria:

          -  Medication with: insulin, glucagon-like peptide-1 (GLP-1)-analogues, sulphonylureas,
             oral corticosteroids, thyreostatic agents or thyroid hormone,
             luteinizing-hormone-releasing hormone (LHRH) analogues

          -  Pregnancy

          -  Known changes in retinal fundus photographs

          -  Known, microalbuminuria

          -  HbA1c &gt;8%

          -  Fasting plasma glucose &gt;10 mmol/l

          -  Medication with metformin, glitazones, gliptins (or acarbose) is allowed but gliptins
             and acarbose need to be stopped 2 days before testing and during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiinamaija Tuomi, MD,lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Folkhalsan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Folkhälsan Research Center</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Soliman A, DeSanctis V, Yassin M, Elalaily R, Eldarsy NE. Continuous glucose monitoring system and new era of early diagnosis of diabetes in high risk groups. Indian J Endocrinol Metab. 2014 May;18(3):274-82. doi: 10.4103/2230-8210.131130. Review.</citation>
    <PMID>24944918</PMID>
  </reference>
  <reference>
    <citation>Wang C, Lv L, Yang Y, Chen D, Liu G, Chen L, Song Y, He L, Li X, Tian H, Jia W, Ran X. Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly diagnosed type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2012 Jun;76(6):810-5. doi: 10.1111/j.1365-2265.2011.04205.x.</citation>
    <PMID>21854404</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2014</study_first_submitted>
  <study_first_submitted_qc>November 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2014</study_first_posted>
  <last_update_submitted>March 11, 2016</last_update_submitted>
  <last_update_submitted_qc>March 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>continuous glucose monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

